In contrast to the EWS/FLI1 fusion which is represented by a t(11;22)(q24;q12), EWS/ERG fusions are frequently cytogenetically not detectable. Three Ewing tumors (ET), two with apparently normal chromosomes 21 and 22, and one ET with a t(2;22)(p25;q12), were studied by FISH on interphase nuclei, metaphase chromosomes and on DNA fibers. EWS/ERG transcripts were detected by RT-PCR in all cases. FISH, using cosmids located proximally (F10, G9) and distally (F7) to the EWS breakpoint region, revealed no detectable separation of these probes in two cases. In contrast, co-hybridization of probe PT1526 containing the ERG breakpoint region with G9 revealed the juxtaposition of two signals per interphase nucleus in all three cases indicating the EWS/ERG fusions. Chromosome preparations displayed the juxtaposed signals on the der(22), and hybridization signals of the probes PT1526 and G9 on the non-rearranged chromosomes 21 and 22 in all cases, respectively. The PT1526 signal on the der(21) was seen only in cases 1 and 2. These results were confirmed by triple-target FISH on tumor DNA fibers. In all three cases, the hybridization pattern F10 – G9 – PT1526 indicates a centromere to telomere orientation. This finding suggests that EWS/ERG fusions in ETs may be generated by an inversion of the ERG gene or a part thereof followed by an insertion into the EWS gene on the der(22). Double-target FISH on interphase nuclei using probes flanking the EWS breakpoint region and probe PT1526 enables the detection of virtually all 22q12 rearrangements in ETs, thus providing a reliable diagnostic assay.   

1.
Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer KM: MIC2 is a specific marker for Ewing’s sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing’s sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 67:1886–1893 (1991).
2.
Bensimon A, Simon A, Chiffaudel A, Croquette V, Heslot F, Bensimon D: Alignment and sensitive detection of DNA by a moving interface. Science 265:2096–2098 (1994).
3.
Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, De JP, Rouleau G, Aurias A, Thomas G: Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162–165 (1992).
4.
Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, Ambros PF, Sheer D, Turc-Carel C, Triche TJ, Aurias A, Thomas G: The Ewing family of tumors – a subgroup of small-round-cell tumors defined by specific chimeric transcripts. New Engl J Med 331:294–299 (1994).
5.
Desmaze C, Zucman J, Delattre O, Thomas G, Aurias A: Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumors. Genes Chrom Cancer 5:30–34 (1992).
6.
Desmaze C, Zucman J, Delattre O, Melot T, Thomas G, Aurias A: Interphase molecular cytogenetics of Ewing’s sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes. Cancer Genet Cytogenet 74:13–18 (1994).
7.
Desmaze C, Brizard F, Turc-Carel C, Melot T, Delattre O, Thomas G, Aurias A: Multiple chromosomal mechanisms generate an EWS/FLI1 or an EWS/ERG fusion gene in Ewing tumors. Cancer Genet Cytogenet 97:12–19 (1997).
8.
Erdel M, Hubalek M, Lingenhel A, Kofler K, Duba HC, Utermann G: Counting the repetitive kringle-IV repeats in the gene encoding human apolipoprotein (a) by fiber-FISH. Nature Genet 21:357–358 (1999).
9.
Florijn RJ, Bonden LA, Vrolijk H, Wiegant J, Vaandrager JW, Baas F, den Dunnen JJ, Tanke HJ, van Ommen GJ, Raap AK: High-resolution DNA Fiber-FISH for genomic DNA mapping and colour bar-coding of large genes. Hum molec Genet 4:831–836 (1995).
10.
Giovannini M, Biegel JA, Serra M, Wang JY, Wei YH, Nycum L, Emanuel BS, Evans GA: EWS-erg and EWS-Fli1 fusion transcripts in Ewing’s sarcoma and primitive neuroectodermal tumors with variant translocations. J Clin Invest 94:489–496 (1994).
11.
Hattinger CM, Rumpler S, Ambros IM, Strehl S, Lion T, Zoubek A, Gadner H, Ambros PF: Demonstration of the translocation der(16)t(1;16)(q12;q11.2) in interphase nuclei of Ewing tumors. Genes Chrom Cancer 17:141–150 (1996).
12.
Hattinger CM, Rumpler S, Strehl S, Ambros IM, Zoubek A, Pötschger U, Gadner H, Ambros PF: Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chrom Cancer 24:243–254 (1999).
13.
Hattinger CM, Zoubek A, Ambros PF: Molecular cytogenetics in Ewing tumors: diagnostic and prognostic information. Onkologie 23:416–422 (2000).
14.
Heiskanen M, Karhu R, Hellsten E, Peltonen L, Kallioniemi OP, Palotie A: High resolution mapping using fluorescence in situ hybridization to extended DNA fibers prepared from agarose-embedded cells. Biotechniques 17:928–933 (1994).
15.
Herrick J, Bensimon A: Imaging of single DNA molecule: application to high-resolution genomic studies. Chrom Res 7:409–423 (1999).
16.
Ichikawa H, Hosoda F, Arai Y, Shimizu K, Ohira M, Ohki M: A Not I restriction map of the entire long arm of human chromosome 21. Nature Genet 4:361–366 (1993).
17.
ISCN 1995: An International System for Human Cytogenetic Nomenclature, Mitelman F (ed) (S. Karger, Basel 1995).
18.
Kaneko Y, Kobayashi H, Handa M, Satake N, Maseki N: EWS-ERG fusion transcript produced by chromosomal insertion in a Ewing sarcoma. Genes Chrom Cancer 18:228–231 (1997).
19.
Kirschner LS, Taymans SE, Pack S, Pack E, Pike BL, Chandrasekharappa SC, Zhuang Z, Stratakis CA: Genomic mapping of chromosomal region 2p15→p21 (D2S378–D2S391): Integration of Genemap’98 within a framework of yeast and bacterial artificial chromosomes. Genomics 62:21–33 (1999).
20.
Lichter P, Cremer T, Borden J, Manuelidis L, Ward DC: Delineation of individual human chromosomes in metaphase and interphase cells by in situ supression hybridization using recombinant DNA libraries. Hum Genet 80:224–234 (1988).
21.
Maho A, Carter A, Bensimon A, Vassart G, Parmentier M: Physical mapping of the CC-chemokine gene cluster on the human 17q11.2 region. Genomics 59:213–223 (1999).
22.
Massey GV, Dunn NL, Heckel JL, Davis EC, Jackson CC, Russell EC: Unusual presentation of Ewing sarcoma with t(21;22) in a 3-year-old boy. J Pediatr Hematol Oncol 18:198–201 (1996).
23.
McManus AP, Gusterson BA, Pinkerton CR, Shipley JM: Diagnosis of Ewing’s sarcoma and related tumours by detection of chromosome 22q12 translocations using fluorescence in situ hybridization on tumour touch imprints. J Pathol 176:137–142 (1995).
24.
Michalet X, Ekong R, Fougerousse F, Rousseaux S, Schurra C, Hornigold N, van SM, Wolfe J, Povey S, Beckmann JS, Bensimon A: Dynamic molecular combing: stretching the whole human genome for high-resolution studies. Science 277:1518–1523 (1997).
25.
Minoletti F, Sozzi G, Tornielli S, Pilotti S, Azzarelli A, Pierotti MA, Radice P: A novel EWS-ERG rearrangement generating two hybrid mRNAs in a peripheral primitive neuroectodermal tumour (pPNET) with a t(15;22) translocation. J Pathol 186:434–437 (1998).
26.
Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, Imai T, Yokoyama K, Soeda E, Ohki M: Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucl Acids Res 23:2762–2769 (1995).
27.
Mugneret F, Favre B, Sidaner I, Petrella T, Flesh M: Translocation (21;22)(q22;q12) in a Ewing sarcoma. New case characterized by cytogenetic analysis and fluorescence in situ hybridization of a fresh tumor. Cancer Genet Cytogenet 87:185–186 (1996).
28.
Parra I, Windle B: High-resolution visual mapping of stretched DNA by fluorescent hybridization. Nature Genet 5:17–21 (1993).
29.
Sandberg AA, Bridge JA: Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors. Cancer Genet Cytogenet 123:1–26 (2000).
30.
Schweizer D, Ambros PF: Chromosome banding: stain combinations for specific regions, in Gosden JR (ed): Methods in Molecular Biology: Chromosome Analysis Protocols, pp 97–112 (Humana Press, Totowa 1994).
31.
Sorensen PH, Lessnick SL, Lopez TD, Liu XF, Triche TJ, Denny CT: A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nature Genet 6:146–151 (1994).
32.
Stark B, Zoubek A, Hattinger C, Jeison M, Gobuzov R, Mor C, Cohen I, Yaniv I, Ambros PF, Kovar H, Zaizov R: Metastatic extraosseous Ewing tumor. Association of the additional translocation der(16)t(1;16) with the variant EWS/ERG rearrangement in a case of cytogenetically inconspicuous chromosome 22. Cancer Genet Cytogenet 87:161–166 (1996).
33.
Stock C, Ambros IM, Lion T, Haas O, Zoubek A, Gadner H, Ambros PF: Detection of numerical and structural chromosome abnormalities in pediatric germ cell tumors by means of interphase cytogenetics. Genes Chrom Cancer 11:40–50 (1994).
34.
Strehl S, Ambros PF: Fluorescence in situ hybridization combined with immunohistochemistry for highly sensitive detection of chromosome 1 aberrations in neuroblastoma. Cytogenet Cell Genet 63:24–28 (1993).
35.
Vaandrager JW, Schuuring E, Zwikstra E, de Boer CJ, Kleiverda KK, van Krieken JH, Kluin NH, van Ommen GJ, Raap AK, Kluin PM: Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood 88:1177–1182 (1996).
36.
Vaandrager JW, Schuuring E, Kluin NH, Dyer MJ, Raap AK, Kluin PM: DNA fiber fluorescence in situ hybridization analysis of immunoglobulin class switching in B-cell neoplasia: aberrant CH gene rearrangements in follicle center-cell lymphoma. Blood 92:2871–2878 (1998).
37.
Vaandrager JW, Schuuring E, Raap AK, Philippo K, Kleiverda KK, Kluin PM: Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chrom Cancer 27:85–94 (2000).
38.
Wiegant J, Kalle W, Mullenders L, Brookes S, Hoovers JM, Dauwerse JG, van Ommen GJ, Raap AK: High-resolution in situ hybridization using DNA halo preparations. Hum molec Genet 1:587–591 (1992).
39.
Zoubek A, Dockhorn DB, Delattre O, Christiansen H, Niggli F, Gatterer MI, Smith TL, Jurgens H, Gadner H, Kovar H: Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 14:1245–1251 (1996).
40.
Zoubek A, Pfleiderer C, Salzer KM, Amann G, Windhager R, Fink FM, Koscielniak E, Delattre O, Strehl S, Ambros PF, Gadner H, Kovar H: Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. Br J Cancer 70:908–913 (1994).
41.
Zucman J, Delattre O, Desmaze C, Plougastel B, Joubert I, Melot T, Peter M, De Jong P, Rouleau G, Aurias A, Thomas G: Cloning and characterization of the Ewing’s sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chrom Cancer 5:271–277 (1992).
42.
Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M, Zucker JM, Triche TJ, Sheer D, Turc-Carel C, Ambros P, Combaret V, Lenoir G, Aurias A, Thomas G, Delattre O: Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 12:4481–4487 (1993).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.